SI21303A - Farmacevtska formulacija olanzapina - Google Patents

Farmacevtska formulacija olanzapina Download PDF

Info

Publication number: SI21303A
Authority: SI; Slovenia
Prior art keywords: weight; pharmaceutical formulation; formulation according; olanzapine; polysaccharide
Prior art date: 2002-10-18

Application number

SI200200255A

Other languages

English (en)

Slovenian (sl)

Inventor

Stanka Perc

Ivanka Banko

Ivanka Kolenc

Original Assignee

Krka, Tovarna Zdravil, D.D.,, Novo Mesto

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-10-18

Filing date

2002-10-18

Publication date

2004-04-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32173824&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI21303(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-10-18 Application filed by Krka, Tovarna Zdravil, D.D.,, Novo Mesto filed Critical Krka, Tovarna Zdravil, D.D.,, Novo Mesto

2002-10-18 Priority to SI200200255A priority Critical patent/SI21303A/sl

2003-10-16 Priority to AT03751723T priority patent/ATE374600T1/de

2003-10-16 Priority to PL376413A priority patent/PL206217B1/pl

2003-10-16 Priority to DK03751723T priority patent/DK1558219T3/da

2003-10-16 Priority to PCT/SI2003/000036 priority patent/WO2004035027A1/en

2003-10-16 Priority to EA200500671A priority patent/EA008516B1/ru

2003-10-16 Priority to CA2502582A priority patent/CA2502582C/en

2003-10-16 Priority to US10/531,540 priority patent/US20050288276A1/en

2003-10-16 Priority to DE60316714T priority patent/DE60316714T2/de

2003-10-16 Priority to SI200331001T priority patent/SI1558219T1/sl

2003-10-16 Priority to HRP20050342AA priority patent/HRP20050342B1/hr

2003-10-16 Priority to YUP-2005/0292A priority patent/RS51488B/sr

2003-10-16 Priority to UAA200504641A priority patent/UA89349C2/uk

2003-10-16 Priority to AU2003269792A priority patent/AU2003269792A1/en

2003-10-16 Priority to EP03751723A priority patent/EP1558219B1/en

2003-10-16 Priority to PT03751723T priority patent/PT1558219E/pt

2003-10-16 Priority to ES03751723T priority patent/ES2295626T3/es

2004-04-30 Publication of SI21303A publication Critical patent/SI21303A/sl

2005-05-13 Priority to NO20052408A priority patent/NO20052408L/no

2007-12-03 Priority to CY20071101537T priority patent/CY1107819T1/el

2011-09-08 Priority to US13/228,028 priority patent/US20110319395A1/en

Links

229960005017 olanzapine Drugs 0.000 title claims abstract description 41
KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 title claims abstract description 40
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 26
150000002772 monosaccharides Chemical class 0.000 claims abstract description 13
239000004480 active ingredient Substances 0.000 claims abstract description 11
150000004676 glycans Chemical class 0.000 claims abstract description 11
229920001282 polysaccharide Polymers 0.000 claims abstract description 11
239000005017 polysaccharide Substances 0.000 claims abstract description 11
229920001542 oligosaccharide Polymers 0.000 claims abstract description 10
150000002482 oligosaccharides Chemical class 0.000 claims abstract description 10
150000003839 salts Chemical class 0.000 claims abstract description 8
239000008240 homogeneous mixture Substances 0.000 claims abstract description 3
239000000203 mixture Substances 0.000 claims description 50
238000009472 formulation Methods 0.000 claims description 28
238000000034 method Methods 0.000 claims description 16
239000011230 binding agent Substances 0.000 claims description 11
229920002472 Starch Polymers 0.000 claims description 10
239000001913 cellulose Substances 0.000 claims description 10
235000019698 starch Nutrition 0.000 claims description 10
229920002678 cellulose Polymers 0.000 claims description 9
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 8
239000008101 lactose Substances 0.000 claims description 8
239000000314 lubricant Substances 0.000 claims description 8
239000008107 starch Substances 0.000 claims description 8
238000002360 preparation method Methods 0.000 claims description 7
239000002904 solvent Substances 0.000 claims description 7
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 6
239000004615 ingredient Substances 0.000 claims description 6
239000007884 disintegrant Substances 0.000 claims description 5
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 4
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 4
229930195725 Mannitol Natural products 0.000 claims description 4
239000000594 mannitol Substances 0.000 claims description 4
235000010355 mannitol Nutrition 0.000 claims description 4
239000007787 solid Substances 0.000 claims description 4
239000000600 sorbitol Substances 0.000 claims description 4
235000010356 sorbitol Nutrition 0.000 claims description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
229930006000 Sucrose Natural products 0.000 claims description 3
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
239000008121 dextrose Substances 0.000 claims description 3
239000000832 lactitol Substances 0.000 claims description 3
VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims description 3
235000010448 lactitol Nutrition 0.000 claims description 3
229960003451 lactitol Drugs 0.000 claims description 3
239000005720 sucrose Substances 0.000 claims description 3
238000000354 decomposition reaction Methods 0.000 claims 1
239000000126 substance Substances 0.000 abstract description 8
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 14
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
229920000881 Modified starch Polymers 0.000 description 9
238000004519 manufacturing process Methods 0.000 description 9
239000000546 pharmaceutical excipient Substances 0.000 description 9
239000012453 solvate Substances 0.000 description 9
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
239000013543 active substance Substances 0.000 description 8
238000002845 discoloration Methods 0.000 description 8
229910002027 silica gel Inorganic materials 0.000 description 8
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 7
150000001875 compounds Chemical class 0.000 description 7
235000019359 magnesium stearate Nutrition 0.000 description 7
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 7
229920000036 polyvinylpyrrolidone Polymers 0.000 description 7
239000000741 silica gel Substances 0.000 description 7
229940032147 starch Drugs 0.000 description 7
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
239000011248 coating agent Substances 0.000 description 6
238000000576 coating method Methods 0.000 description 6
239000000945 filler Substances 0.000 description 6
229920000168 Microcrystalline cellulose Polymers 0.000 description 5
235000010980 cellulose Nutrition 0.000 description 5
235000019813 microcrystalline cellulose Nutrition 0.000 description 5
229940016286 microcrystalline cellulose Drugs 0.000 description 5
239000008108 microcrystalline cellulose Substances 0.000 description 5
229940069328 povidone Drugs 0.000 description 5
239000011734 sodium Substances 0.000 description 5
229910052708 sodium Inorganic materials 0.000 description 5
238000005550 wet granulation Methods 0.000 description 5
229920002261 Corn starch Polymers 0.000 description 4
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
239000008120 corn starch Substances 0.000 description 4
229940099112 cornstarch Drugs 0.000 description 4
229960001375 lactose Drugs 0.000 description 4
239000011777 magnesium Substances 0.000 description 4
229910052749 magnesium Inorganic materials 0.000 description 4
238000012360 testing method Methods 0.000 description 4
-1 4-methyl-1-piperazinyl Chemical group 0.000 description 3
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
238000002156 mixing Methods 0.000 description 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
208000028017 Psychotic disease Diseases 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
230000003042 antagnostic effect Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
229910000389 calcium phosphate Inorganic materials 0.000 description 2
235000011010 calcium phosphates Nutrition 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
238000007906 compression Methods 0.000 description 2
230000006835 compression Effects 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
238000001035 drying Methods 0.000 description 2
238000005469 granulation Methods 0.000 description 2
230000003179 granulation Effects 0.000 description 2
150000004677 hydrates Chemical class 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
239000002245 particle Substances 0.000 description 2
239000006187 pill Substances 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
229920003124 powdered cellulose Polymers 0.000 description 2
235000019814 powdered cellulose Nutrition 0.000 description 2
239000002994 raw material Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
102000056834 5-HT2 Serotonin Receptors Human genes 0.000 description 1
108091005479 5-HT2 receptors Proteins 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
206010026749 Mania Diseases 0.000 description 1
239000004368 Modified starch Substances 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000001785 acacia senegal l. willd gum Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
230000001078 anti-cholinergic effect Effects 0.000 description 1
230000003474 anti-emetic effect Effects 0.000 description 1
230000001022 anti-muscarinic effect Effects 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
239000002249 anxiolytic agent Substances 0.000 description 1
230000000949 anxiolytic effect Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
239000008119 colloidal silica Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
229960001681 croscarmellose sodium Drugs 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
239000008380 degradant Substances 0.000 description 1
150000004683 dihydrates Chemical class 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000003210 dopamine receptor blocking agent Substances 0.000 description 1
239000002706 dry binder Substances 0.000 description 1
238000007908 dry granulation Methods 0.000 description 1
238000005265 energy consumption Methods 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
229960002464 fluoxetine Drugs 0.000 description 1
239000011888 foil Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
229960003511 macrogol Drugs 0.000 description 1
229940057948 magnesium stearate Drugs 0.000 description 1
229940095102 methyl benzoate Drugs 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
235000019426 modified starch Nutrition 0.000 description 1
150000004682 monohydrates Chemical class 0.000 description 1
239000003176 neuroleptic agent Substances 0.000 description 1
230000000701 neuroleptic effect Effects 0.000 description 1
230000002474 noradrenergic effect Effects 0.000 description 1
238000010899 nucleation Methods 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
238000005457 optimization Methods 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000000047 product Substances 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
238000011160 research Methods 0.000 description 1
201000000980 schizophrenia Diseases 0.000 description 1
230000000698 schizophrenic effect Effects 0.000 description 1
238000005204 segregation Methods 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000007916 tablet composition Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
238000010200 validation analysis Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
229930195727 α-lactose Natural products 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Biophysics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Molecular Biology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

SI200200255A 2002-10-18 2002-10-18 Farmacevtska formulacija olanzapina SI21303A (sl)

Priority Applications (20)

Application Number	Priority Date	Filing Date	Title
SI200200255A SI21303A (sl)	2002-10-18	2002-10-18	Farmacevtska formulacija olanzapina
ES03751723T ES2295626T3 (es)	2002-10-18	2003-10-16	Formulacion farmaceutica de olanzapina.
DE60316714T DE60316714T2 (de)	2002-10-18	2003-10-16	Pharmazeutische formulierung enthaltend olanzapin
HRP20050342AA HRP20050342B1 (hr)	2002-10-18	2003-10-16	Farmaceutska formulacija olanzapina
DK03751723T DK1558219T3 (da)	2002-10-18	2003-10-16	Farmaceutisk formulering af olanzapin
PCT/SI2003/000036 WO2004035027A1 (en)	2002-10-18	2003-10-16	Pharmaceutical formulation of olanzapine
EA200500671A EA008516B1 (ru)	2002-10-18	2003-10-16	Фармацевтический состав оланзапина
CA2502582A CA2502582C (en)	2002-10-18	2003-10-16	Pharmaceutical formulation of olanzapine
US10/531,540 US20050288276A1 (en)	2002-10-18	2003-10-16	Pharmaceutical formulation of olanzapine
AT03751723T ATE374600T1 (de)	2002-10-18	2003-10-16	Pharmazeutische formulierung enthaltend olanzapin
SI200331001T SI1558219T1 (sl)	2002-10-18	2003-10-16	Farmacevtska formulacija olanzapina
PL376413A PL206217B1 (pl)	2002-10-18	2003-10-16	Preparat farmaceutyczny olanzapiny i sposób wytwarzania preparatu
YUP-2005/0292A RS51488B (sr)	2002-10-18	2003-10-16	Farmaceutska formulacija olanzapina
UAA200504641A UA89349C2 (uk)	2002-10-18	2003-10-16	Таблетка без покриття, яка містить оланзапін, та спосіб її одержання
AU2003269792A AU2003269792A1 (en)	2002-10-18	2003-10-16	Pharmaceutical formulation of olanzapine
EP03751723A EP1558219B1 (en)	2002-10-18	2003-10-16	Pharmaceutical formulation of olanzapine
PT03751723T PT1558219E (pt)	2002-10-18	2003-10-16	Formulação farmacêutica de olanzapina
NO20052408A NO20052408L (no)	2002-10-18	2005-05-13	Farmasoytisk formulering av olanzapin
CY20071101537T CY1107819T1 (el)	2002-10-18	2007-12-03	Φαρμακευτικη διαμορφωση της ολανζαπινης
US13/228,028 US20110319395A1 (en)	2002-10-18	2011-09-08	Pharmaceutical Formulation of Olanzapine

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
SI200200255A SI21303A (sl)	2002-10-18	2002-10-18	Farmacevtska formulacija olanzapina

Publications (1)

Publication Number	Publication Date
SI21303A true SI21303A (sl)	2004-04-30

Family

ID=32173824

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SI200200255A SI21303A (sl)	2002-10-18	2002-10-18	Farmacevtska formulacija olanzapina
SI200331001T SI1558219T1 (sl)	2002-10-18	2003-10-16	Farmacevtska formulacija olanzapina

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SI200331001T SI1558219T1 (sl)	2002-10-18	2003-10-16	Farmacevtska formulacija olanzapina

Country Status (18)

Country	Link
US (2)	US20050288276A1 (da)
EP (1)	EP1558219B1 (da)
AT (1)	ATE374600T1 (da)
AU (1)	AU2003269792A1 (da)
CA (1)	CA2502582C (da)
CY (1)	CY1107819T1 (da)
DE (1)	DE60316714T2 (da)
DK (1)	DK1558219T3 (da)
EA (1)	EA008516B1 (da)
ES (1)	ES2295626T3 (da)
HR (1)	HRP20050342B1 (da)
NO (1)	NO20052408L (da)
PL (1)	PL206217B1 (da)
PT (1)	PT1558219E (da)
RS (1)	RS51488B (da)
SI (2)	SI21303A (da)
UA (1)	UA89349C2 (da)
WO (1)	WO2004035027A1 (da)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CZ297214B6 (cs) *	2005-02-02	2006-10-11	Zentiva, A. S.	Lécivý prípravek obsahující jako úcinnou slozku olanzapin a zpusob jeho výroby

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2006018318A1 (en) *	2004-08-18	2006-02-23	Synthon B.V.	Liquid paroxetine compositions
GB0522473D0 (en) *	2005-11-03	2005-12-14	Actavis Group	A pharmaceutical formulation
GB0522474D0 (en) *	2005-11-03	2005-12-14	Actavis Group	A pharmaceutical formulation
ES2279715B1 (es)	2005-12-26	2008-06-01	Laboratorios Lesvi, S.L.	Formulacion oral de olanzapina.
US20070293479A1 (en) *	2006-05-18	2007-12-20	Osinga Niels J	Olanzapine pharmaceutical composition
US20080138409A1 (en) *	2006-09-29	2008-06-12	Osinga Niels J	Olanzapine pharmaceutical composition
WO2012014012A1 (es) *	2010-07-27	2012-02-02	Laboratorios Andrómaco S.A.	Procedimiento para preparar comprimidos de disolucion rapida oral que comprenden la forma i de olanzapina, los comprimidos obtenidos y su uso para el tratamiento de la esquizofrenia.
WO2012153347A2 (en)	2011-05-04	2012-11-15	Zentiva K.S.	Oral pharmaceutical composition of olanzapine form 1
WO2013066280A1 (en) *	2011-10-31	2013-05-10	Mahmut Bilgic	Water soluble antipsychotic formulations
CN103919782B (zh) *	2013-01-15	2016-12-28	天津药物研究院有限公司	一种含有奥氮平的药物组合物及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2115116C3 (de) *	1970-03-27	1982-04-15	Sankyo Co., Ltd., Tokyo	Gleitmittel und Verfahren zu dessen Herstellung
US5229382A (en) *	1990-04-25	1993-07-20	Lilly Industries Limited	2-methyl-thieno-benzodiazepine
GB9009229D0 (en)	1990-04-25	1990-06-20	Lilly Industries Ltd	Pharmaceutical compounds
CN1230883A (zh) *	1996-09-24	1999-10-06	伊莱利利公司	包衣颗粒制剂
US6348458B1 (en) *	1999-12-28	2002-02-19	U & I Pharmaceuticals Ltd.	Polymorphic forms of olanzapine
JP4530664B2 (ja) *	2001-12-24	2010-08-25	サン・ファーマシューティカル・インダストリーズ・リミテッド	２−メチル−４−（４−メチル−１−ピペラジニル）−１０Ｈ−チエノ［２，３−ｂ］［１，５］ベンゾジアゼピンの結晶形Ｉ、この結晶形Ｉの製造方法、及び医薬組成物
AU2002255196A1 (en) *	2002-04-18	2003-10-27	Dr. Reddy's Laboratories Ltd.	Rapidly dispersing solid oral compositions

2002
- 2002-10-18 SI SI200200255A patent/SI21303A/sl not_active IP Right Cessation
2003
- 2003-10-16 WO PCT/SI2003/000036 patent/WO2004035027A1/en not_active Ceased
- 2003-10-16 HR HRP20050342AA patent/HRP20050342B1/hr not_active IP Right Cessation
- 2003-10-16 AT AT03751723T patent/ATE374600T1/de active
- 2003-10-16 PL PL376413A patent/PL206217B1/pl unknown
- 2003-10-16 US US10/531,540 patent/US20050288276A1/en not_active Abandoned
- 2003-10-16 EP EP03751723A patent/EP1558219B1/en not_active Revoked
- 2003-10-16 AU AU2003269792A patent/AU2003269792A1/en not_active Abandoned
- 2003-10-16 PT PT03751723T patent/PT1558219E/pt unknown
- 2003-10-16 ES ES03751723T patent/ES2295626T3/es not_active Expired - Lifetime
- 2003-10-16 DK DK03751723T patent/DK1558219T3/da active
- 2003-10-16 SI SI200331001T patent/SI1558219T1/sl unknown
- 2003-10-16 DE DE60316714T patent/DE60316714T2/de not_active Expired - Lifetime
- 2003-10-16 EA EA200500671A patent/EA008516B1/ru not_active IP Right Cessation
- 2003-10-16 CA CA2502582A patent/CA2502582C/en not_active Expired - Fee Related
- 2003-10-16 UA UAA200504641A patent/UA89349C2/uk unknown
- 2003-10-16 RS YUP-2005/0292A patent/RS51488B/sr unknown
2005
- 2005-05-13 NO NO20052408A patent/NO20052408L/no not_active Application Discontinuation
2007
- 2007-12-03 CY CY20071101537T patent/CY1107819T1/el unknown
2011
- 2011-09-08 US US13/228,028 patent/US20110319395A1/en not_active Abandoned

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CZ297214B6 (cs) *	2005-02-02	2006-10-11	Zentiva, A. S.	Lécivý prípravek obsahující jako úcinnou slozku olanzapin a zpusob jeho výroby

Also Published As

Publication number	Publication date
US20110319395A1 (en)	2011-12-29
ATE374600T1 (de)	2007-10-15
HRP20050342A2 (hr)	2006-04-30
SI1558219T1 (sl)	2008-02-29
RS51488B (sr)	2011-04-30
DK1558219T3 (da)	2007-10-29
AU2003269792A1 (en)	2004-05-04
RS20050292A (sr)	2007-08-03
NO20052408D0 (no)	2005-05-13
EA008516B1 (ru)	2007-06-29
PT1558219E (pt)	2008-01-04
EP1558219B1 (en)	2007-10-03
CA2502582C (en)	2010-08-03
WO2004035027A1 (en)	2004-04-29
HRP20050342B1 (hr)	2013-11-08
US20050288276A1 (en)	2005-12-29
PL376413A1 (en)	2005-12-27
CA2502582A1 (en)	2004-04-29
EA200500671A1 (ru)	2005-10-27
PL206217B1 (pl)	2010-07-30
EP1558219A1 (en)	2005-08-03
UA89349C2 (uk)	2010-01-25
NO20052408L (no)	2005-07-04
ES2295626T3 (es)	2008-04-16
DE60316714T2 (de)	2008-07-17
DE60316714D1 (de)	2007-11-15
CY1107819T1 (el)	2013-06-19

Legal Events

Date	Code	Title	Description
2005-01-10	IF	Valid on the event date
2012-11-30	KO00	Lapse of patent	Effective date: 20121025

Publication	Publication Date	Title
US20110319395A1 (en)	2011-12-29	Pharmaceutical Formulation of Olanzapine
EP1008354B1 (en)	2008-06-04	Immediately disintegrable medicinal compositions
US9622976B2 (en)	2017-04-18	Pharmaceutical composition
US7351429B1 (en)	2008-04-01	Oral solid preparation
ZA200706692B (en)	2008-07-30	Orally disintegrating composition of olanzapine of donepezil
SK176798A3 (en)	2000-04-10	Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug
WO2009034541A9 (en)	2009-12-30	Controlled release pharmaceutical dosage forms of trimetazidine
SK13642001A3 (sk)	2002-03-05	Farmaceutický prípravok na orálne podávanie obsahujúci tolperizón
MX2009002336A (es)	2009-03-20	Composiciones de imatinib.
US20110195120A2 (en)	2011-08-11	Sustained Release Pharmaceutical Composition Containing Metformin Hydrochloride
EP3437646A1 (en)	2019-02-06	Oral preparation having exceptional elutability
CA2696977C (en)	2012-12-04	Improved pharmaceutical composition containing a pyrrolidone anticonvulsant agent and method for the preparation thereof
US20020123503A1 (en)	2002-09-05	Cabergoline pharmaceutical compositions and methods of use thereof
WO2010026597A1 (en)	2010-03-11	Oral dosage forms of linezolid and processes for their preparation
EP3426231A1 (en)	2019-01-16	Modified release nicergoline compositions
HU225779B1 (en)	2007-08-28	Pharmaceutical composition containing paracetamol and drotaverine and process for producing it
CN101484141A (zh)	2009-07-15	包含抗氧化剂的稳定的奥氮平制剂
EP2403500A2 (en)	2012-01-11	Stable olanzapine tablets and the process for its preparation
WO2007049304A2 (en)	2007-05-03	Stable coated pharmaceutical formulation of olanzapine and process for preparing the same
BG65912B1 (bg)	2010-05-31	Лекарствена форма на комбиниран препарат и метод за нейното получаване
BG65676B1 (bg)	2009-06-30	Лекарствена форма и метод за нейното получаване
ITMI20072205A1 (it)	2009-05-22	Compresse orali di desmopressina e loro metodo di preparazione

SI21303A - Farmacevtska formulacija olanzapina - Google Patents

Info

Links

Classifications

Landscapes

Priority Applications (20)

Applications Claiming Priority (1)

Publications (1)

Family

ID=32173824

Family Applications (2)

Family Applications After (1)

Country Status (18)

Cited By (1)

Families Citing this family (10)

Family Cites Families (7)

Cited By (1)

Also Published As

Similar Documents

Legal Events